Cullinan Therapeutics (CGEM) Cash from Operations (2020 - 2023)
Historic Cash from Operations for Cullinan Therapeutics (CGEM) over the last 4 years, with Q4 2023 value amounting to -$18.1 million.
- Cullinan Therapeutics' Cash from Operations rose 2742.67% to -$18.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$134.3 million, marking a year-over-year decrease of 600.88%. This contributed to the annual value of -$145.3 million for FY2024, which is 821.3% down from last year.
- As of Q4 2023, Cullinan Therapeutics' Cash from Operations stood at -$18.1 million, which was up 2742.67% from -$34.1 million recorded in Q3 2023.
- In the past 5 years, Cullinan Therapeutics' Cash from Operations ranged from a high of -$1.5 million in Q1 2021 and a low of -$54.4 million during Q3 2022
- In the last 4 years, Cullinan Therapeutics' Cash from Operations had a median value of -$17.2 million in 2021 and averaged -$20.9 million.
- Its Cash from Operations has fluctuated over the past 5 years, first skyrocketed by 6979.06% in 2021, then crashed by 134607.26% in 2022.
- Over the past 4 years, Cullinan Therapeutics' Cash from Operations (Quarter) stood at -$9.4 million in 2020, then plummeted by 60.78% to -$15.2 million in 2021, then plummeted by 64.68% to -$25.0 million in 2022, then grew by 27.43% to -$18.1 million in 2023.
- Its Cash from Operations stands at -$18.1 million for Q4 2023, versus -$34.1 million for Q3 2023 and -$31.0 million for Q2 2023.